Hairy cell leukemia treatment, Lumoxiti, receives FDA nod
by Press Release from Outbreak News Today on (#3YVBT)
The U.S. Food and Drug Administration this week approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first ["]
The post Hairy cell leukemia treatment, Lumoxiti, receives FDA nod appeared first on Outbreak News Today.